First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses

Human Vaccines

Volumn 6, Issue 12, 2010, Pages 1007-1015

  Ottenhoff, Tom H M ^a   Doherty, T Mark ^c   Van Dissel, Jaap T ^a   Bang, Peter ^b   Lingnau, Karen ^d   Kromann, Ingrid ^b   Andersen, Peter ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STATENS SERUM INSTITUT   (Denmark)

^c Dept of Infectious Disease Immunology ^*  (Denmark)

^d INTERCELL AG   (Austria)

Author keywords

Adjuvant; Clinical trial; Immune responses; Long term memory; Subunit; Tuberculosis; Vaccine

Indexed keywords

ANTIGEN 85B EARLY SECRETORY ANTIGENIC TARGET 6 FUSION PROTEIN VACCINE; BCG VACCINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; GAMMA INTERFERON; IC 31; INTERLEUKIN 12; KALLIKREIN OLIGODEOXYNUCLEOTIDE 1A FUSION PROTEIN VACCINE; MYCOBACTERIUM VACCINE; PHOSPHORYL LIPID A; RECOMBINANT DNA; RECOMBINANT PROTEIN; SUBUNIT VACCINE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS VECTOR;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; BACTERIUM CULTURE; CD4+ T LYMPHOCYTE; CELL DEATH; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE TRANSMISSION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FOLLOW UP; GRANULOMA; GUINEA PIG; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; MACROPHAGE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIMATE; REVIEW; TH1 CELL; TREATMENT RESPONSE; TUBERCULOSIS; VACCINATION; VACCINE PRODUCTION;

ANIMALS; GUINEA PIGS; HUMANS; INTERFERON-GAMMA; MICE; MYCOBACTERIUM TUBERCULOSIS; TH1 CELLS; TIME FACTORS; TUBERCULOSIS VACCINES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 78751676191     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.12.13143     Document Type: Review

References (74)

1. Maher D, Dye C, Floyd K, Pantoja A, Lonnroth K, Reid A, et al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ 2007; 85:341-7.
2. WHO. WHO report 2009. Global Tuberculosis control - Epidemiology, Strategy, Financing. Geneva 2009.
3. Jassal M, Bishai WR. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009; 9:19-30.
4. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60 year follow-up study. JAMA 2004; 291:2086-91.
5. Mahomed H, Kibel M, Hawkridge T, Schaaf HS, Hanekom WA, Iloni K, et al. The impact of a change in bacille Calmette-Guerin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa. Pediatr Infect Dis J 2006; 25:1167-72.
6. Sterne JA, Rodrigues LC, Guedes IN. Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis 1998; 2:200-7.
7. Hesseling AC, Johnson LF, Jaspan H, Cotton MF, Whitelaw A, Schaaf HS, et al. Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bull World Health Organ 2009; 87:505-11.
8. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-8. (Pubitemid 44855247)
9. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002; 32:97-105. (Pubitemid 34977203)
10. Hesseling AC, Cotton MF, Fordham von RC, Graham SM, Gie RP, Hussey GD. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008; 12:1376-9.
11. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006; 4:469-76.
12. Doherty TM, Dietrich J, Billeskov R. Tuberculosis subunit vaccines: from basic science to clinical testing. Expert Opin Biol Ther 2007; 7:1539-49. (Pubitemid 47597142)
13. Ottenhoff TH. Overcoming the global crisis: "yes, we can", but also for TB...? Eur J Immunol 2009; 39:2014-20.
14. Andersen P, Doherty TM. The success and failure of. Nat Rev Microbiol 2005; 3:656-62.
15. Brandt L, Feino CJ, Weinreich OA, Chilima B, Hirsch P, Appelberg R, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70:672-8.
16. Buddle BM, Wards BJ, Aldwell FE, Collins DM, de Lisle GW. Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 2002; 20:1126-33.
17. Kaufmann SH. Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 2006; 6:699-704. (Pubitemid 44298219)
18. McShane H. Developing an improved vaccine against tuberculosis. Expert Rev Vaccines 2004; 3:299-306. (Pubitemid 38796868)
19. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun 2001; 69:1722-8.
20. de JR, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280:1435-8.
21. Tso EY, Tsang OT, Lam B, Ng TK, Lim W, Lai TS. Natural course of severe acute respiratory syndrome-associated coronavirus immunoglobulin after infection. J Infect Dis 2004; 190:1706-7.
22. Saunders BM, Frank AA, Orme IM, Cooper AM. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002; 216:65-72.
23. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-54.
24. Scanga CA, Mohan VP, Yu K, Joseph H, Tanaka K, Chan J, et al. Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med 2000; 192:347-58.
25. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
26. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561-72.
27. Agger EM, Andersen P. Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 2001; 19:2298-302.
28. Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, Lienhardt C, et al. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infect Dis 2006; 6:522-8.
29. Soares AP, Scriba TJ, Joseph S, Harbacheuski R, Murray RA, Gelderbloem SJ, et al. Bacillus Calmette- Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008; 180:3569-77.
30. Hubbard RD, Flory CM, Collins FM. Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol 1992; 87:94-8.
31. Pal PG, Horwitz MA. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 1992; 60:4781-92.
32. Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994; 62:2536-44.
33. Andersen AB, Andersen P, Ljungqvist L. Structure and function of a 40,000 molecular-weight protein antigen of Mycobacterium tuberculosis. Infect Immun 1992; 60:2317-23.
34. Langermans JA, Doherty TM, Vervenne RA, van der Laan T, Lyashchenko K, Greenwald R, et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005; 23:2740-50.
35. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005; 85:29-38.
36. Arend SM, Andersen P, van Meijgaarden KE, Skjot RL, Subronto YW, van Dissel JT, et al. Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6 kDa protein and culture filtrate protein 10. J Infect Dis 2000; 181:1850-4. (Pubitemid 30387793)
37. Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004; 72:6148-50. (Pubitemid 39303732)
38. Ottenhoff TH, Lewinsohn DA, Lewinson DM. Human CD4 and CD8 T cell responses to Mycobacterium tuberculosis: antigen specificity, function, implications and applications. In: Kaufmann SHE, Britton WJ, Editors. Handbook of Tuberculosis. Immunology and Cell Biology. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany 2010; 119-56.
39. Doherty TM, Olsen AW, Weischenfeldt J, Huygen K, D'Souza S, Kondratieva TK, et al. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J Infect Dis 2004; 190:2146-53.
40. Agger EM, Cassidy JP, Brady J, Korsholm KS, Vingsbo- Lundberg C, Andersen P. Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology 2008; 124:175-85.
41. McKee AS, Munks MW, MacLeod MK, Fleenor CJ, Van Rooijen N, Kappler JW, et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009; 183:4403-14.
42. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82:488-96. (Pubitemid 39421058)
43. Skeiky YA, Alderson MR, Ovendale PJ, Guderian JA, Brandt L, Dillon DC, et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 2004; 172:7618-28. (Pubitemid 38747626)
44. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect Immun 1997; 65:623-9.
45. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000; 68:791-5.
46. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 2004; 72:1608-17.
47. Schoenen H, Bodendorfer B, Hitchens K, Manzanero S, Werninghaus K, Nimmerjahn F, et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 2010; 184:2756-60.
48. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, Perrie Y, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 2005; 1718:22-31.
49. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, Aagaard C, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008; 3:3116.
50. Kamath AT, Valenti MP, Rochat AF, Agger EM, Lingnau K, von Gabain A, et al. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur J Immunol 2008; 38:1247-56.
51. Lingnau K, Riedl K, von Gabain A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 2007; 6:741-6.
52. Agger EM, Rosenkrands I, Olsen AW, Hatch G, Williams A, Kritsch C, et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 2006; 24:5452-60.
53. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, Lingnau K, et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010; 28:3571-81.
54. Kamath AT, Rochat AF, Valenti MP, Agger EM, Lingnau K, Andersen P, et al. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS One 2008; 3:3683.
55. Christensen D, Kirby D, Foged C, Agger EM, Andersen P, Perrie Y, et al. alpha,alpha'-trehalose 6,6'-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochim Biophys Acta 2008; 1778:1365-73.
56. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 178:2243-7.
57. McMurray DN. A coordinated strategy for evaluating new vaccines for human and animal tuberculosis. Tuberculosis (Edinb) 2001; 81:141-6.
58. Dannenberg AM Jr. Pathogenesis of pulmonary Mycobacterium bovis infection: basic principles established by the rabbit model. Tuberculosis (Edinb) 2001; 81:87-96.
59. Wiegeshaus EH, McMurray DN, Grover AA, Harding GE, Smith DW. Host-parasite relationships in experimental airborne tuberculosis. 3. Relevance of microbial enumeration to acquired resistance in guinea pigs. Am Rev Respir Dis 1970; 102:422-9.
60. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50.
61. +T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40:2211-20.
62. Roukens AH, Vossen AC, van Dissel JT, Visser LG. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 2009; 27:2408-9.
63. Andersen P, Doherty TM. TB subunit vaccines - putting the pieces together. Microbes Infect 2005; 7:911-21.
64. Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006; 24:5461-72.
65. Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De Kock E, Pavithran P, et al. The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 2009; 5:475-82.
66. Aagaard C, Dietrich J, Doherty M, Andersen P. TB vaccines: current status and future perspectives. Immunol Cell Biol 2009; 87:279-86.
67. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004; 10:1240-4.
68. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010; 375:2110-9.
69. Smith SG, Joosten SA, Verscheure V, Pathan AA, McShane H, Ottenhoff TH, et al. Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One 2009; 4:7972.
70. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96:29-35.
71. Weir RE, Gorak-Stolinska P, Floyd S, Lalor MK, Stenson S, Branson K, et al. Persistence of the immune response induced by BCG vaccination. BMC Infect Dis 2008; 8:9.
72. Baumann S, Nasser EA, Kaufmann SH. Progress in tuberculosis vaccine development. Curr Opin Immunol 2006; 18:438-48.
73. Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature 2000; 406:793-8.
74. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, Seder RA, et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009; 182:8047-55.